Merck KGaA Life Science (MilliporeSigma)(MRK.DE)
HQ DE30% share
chemical · input
Lipid nanoparticle (LNP) lipid components
Ionizable lipid, phospholipid, cholesterol, and PEG-lipid formulated into nanoparticles for mRNA cancer vaccine and siRNA drug delivery.
3
Source countries
4
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on lipid nanoparticle (lnp) lipid components somewhere upstream in their supply chain.
Where it comes from
Source countries
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| DEGermany/Europe | 30% |
| CHSwitzerland | 25% |
| USUnited States of America | 25% |
Who makes it
Supplier companies
4 companies produce lipid nanoparticle (lnp) lipid components.
CordenPharma
HQ CH25% share
Swiss CDMO operating European and US API manufacturing sites; primary lipid partner for Moderna; manufactures SM-102 and full LNP lipid component portfolio including ionizable, PEGylated, phosphocholine, and plant sterols; claims largest complex lipid capacity globally
Thermo Fisher Scientific(TMO)
HQ US25% share
Evonik Industries AG(EVK)
HQ DE
Evonik Industries AG (XETRA: EVK; Essen Germany; MDAX listed); world's largest DL-methionine producer under the MetAMINO brand. Total DL-methionine capacity exceeds 700,000 MT/year across three continental hubs: Jurong Island Singapore (~340,000 MT/year — world's largest single methionine complex, expanded +40k MT August 2024), Theodore Mobile County Alabama USA (~245,000 MT/year), and Antwerp Belgium (~120,000 MT/year). The Wesseling Germany DL-Met line closed Q1 2021 as Evonik consolidated production to the three-hub network. Evonik first commercialized DL-methionine synthesis in the 1950s under predecessor Degussa. MetAMINO is Evonik's largest single product. ~30-32% global market share. In February 2022 Evonik announced a $176.5M investment in a new methyl mercaptan (MMP intermediate feedstock) plant at the Alabama site.